Export 8 results:
Author Title [ Type(Desc)] Year
Filters: Author is Winokur, PL  [Clear All Filters]
Journal Article
R. W. Frenck, Jr, Belshe, R., Brady, R. C., Winokur, P. L., Campbell, J. D., Treanor, J., Hay, C. M., Dekker, C. L., Walter, Jr., E. B., TR, C., KM, E., Hill, H., Wolff, M., Leduc, T., and Tornieporth, N., Comparison of the Immunogenicity and Safety of a Split-Virion, Inactivated, Trivalent Influenza Vaccine (Fluzone®) Administered by Intradermal and Intramuscular Route in Healthy Adults, Vaccine, vol. 29, pp. 5666-5674, 2011.
W. H. Chen, Winokur, P. L., Edwards, K. M., Jackson, L. A., Wald, A., Walter, E. B., Noah, D. L., Wolff, M., Kotloff, K. L., Chua, J. V., Hutter, J., Stephens, I., Stapleton, J., Meier, J., Callahan, S. T., Creech, C. B., Halasa, N. B., Johnston, C., Dolor, R. J., Schmader, K. E., Woods, C. W., and Hill, H., Phase 2 Assessment of the Safety and Immunogenicity of Two Inactivated Pandemic Monovalent H1N1 Vaccines in Adults as a Component of the U.S. Pandemic Preparedness Plan in 2009, Vaccine, vol. 13, pp. 4240-4248, 2012.
S. E. Frey, Winokur, P. L., Hill, H., Goll, J. B., Chaplin, P., and Belshe, R. B., Phase II Randomized, Double-Blinded Comparison of a Single High Dose (5×10(8) TCID 50) of Modified Vaccinia Ankara Compared to a Standard Dose (1×10(8) TCID50) in Healthy Vaccinia-Naïve Individuals, Vaccine, vol. 32, pp. 2732-2739, 2014.
S. E. Frey, Bernstein, D. I., Gerber, M. A., Keyserling, H. L., Munoz, F. M., Winokur, P. L., Turley, C. B., Rupp, R. E., Hill, H., Wolff, M., Noah, D. L., Ross, A. C., Cress, G., and Belshe, R. B., Safety and Immune Responses in Children After Concurrent or Sequential 2009 H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations, J Infect Dis, vol. 206, pp. 828-837, 2012.
P. L. Winokur, Patel, S. M., Brady, R., Chen, W. H., El-Kamary, S. S., Edwards, K., Creech, C. B., Frey, S., Keitel, W. A., Belshe, R., Walter, E., Bellamy, A., Hill, H., and Group, T. V. T. E. U. - H. 3Nv, Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine, J Infect Dis, vol. 212, pp. 525-530, 2015.
W. A. Keitel, Jackson, L. A., Edupuganti, S., Winokur, P. L., Mulligan, M. J., Thornburg, N. J., Patel, S. M., Rouphael, N. G., Lai, L., Bangaru, S., McNeal, M. M., Bellamy, A. R., Hill, H. R., and Group, T. V. T. E. U. - H. 3Nv, Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons >/=18 Years Old, J Infect Dis, vol. 212, pp. 552-561, 2015.
P. L. Winokur, Chaloner, K., Doem, G. V., Ferreira, J., and Apicella, M. A., Safety and Immunological Outcomes Following Human Inoculation with Nontypeable Haemophilus Influenzae, J Infect Dis, vol. 208, pp. 728-738, 2013.
T. Talbot, Stapleton, J. T., Brady, R. C., Winokur, P. L., Bernstein, D. I., Germanson, T., Yoder, S., Rock, M. T., Crowe, J. E., and Edwards, K. M., Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine, J Amer Med Assn, vol. 292, pp. 1205-1212, 2004.